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ABSTRACT 
Pediatric soft tissue tumors are relatively rare and show significant overlap in morphology and 
immunoprofile, often posing diagnostic and management challenges. Thus their classification 
remains often subjective or lumped under ‘unclassified categories’, as a number of lesions lack 
objective and reproducible criteria in diagnosis. Although in a subset of cases 
immunohistochemistry has been proved useful to identify a specific line of differentiation, most 
tumors lack a readily defined histogenesis, being characterized by a rather non-specific 
immunoprofile. Furthermore, tumors with an ambiguous diagnosis are difficult to grade and their 
risk of malignancy or clinical management remains uncertain. Advances in molecular genetics, 
including the more wide application of next generation sequencing in routine clinical practice, 
have improved diagnosis and refined classification based on objective molecular markers. 
Importantly, some soft tissue tumors in children are characterized by recurrent gene fusions 
involving either growth factors (e.g. PDGFB) or protein kinases (e.g. ALK, ROS, NTRK, 
BRAF), which have a paved the way for new targeted treatments that block the respective 
upregulated downstream pathways. However, the majority of gene fusions or mutations detected 
in soft tissue tumors result in an abnormal function of transcription factors or chromatin 
remodeling.
1
 The present review focuses on the latest genetic discoveries in the spectrum of both 
benign and malignant pediatric soft tissue neoplasia. These genetic abnormalities promiss to 
provide relevant insight for their proper classification, prognosis, and treatment. The entities 
discussed herein are grouped either based on their shared genetic mechanism or based on their 
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I. PEDIATRIC MESENCHYMAL TUMORS DRIVEN BY RECURRENT KINASE 
FUSIONS  
1. INFANTILE FIBROSARCOMA AND RELATED ENTITIES.  
A. Infantile Fibrosarcoma (IFS) with canonical ETV6-NTRK3 fusions. IFS is a childhood 
sarcoma that typically presents at birth or in the first year of life.
2
 IFS has a variable anatomic 
distribution, with presentation in the distal upper or lower extremities, but also in the trunk and 
head and neck area. Compared to other high-grade childhood sarcomas, IFS has a favorable 
outcome, with conservative surgical resection being the preferred therapy, in particular when 
aiming for limb salvage. Although cytotoxic chemotherapy has shown activity in IFS, its use is 
limited to selective cases, unamenable to surgery. Only recently, targeted therapy with 
Larotrectinib, a selective NTRK inhibitor, has been administered in advanced stage IFS with 
promising results.
3
 Histologically, IFS is a monomorphic spindle cell sarcoma composed of 
mitotically active, immature fibroblastic spindle cells arranged in cellular sheets and fascicles, 
sometimes with prominent lymphocytic infiltrate and hemangiopericytoma-like vascular pattern. 
The immunoprofile of IFS is rather nonspecific, with only a small subset showing focal 
expression of SMA or CD34. IHC using a Pan-TRK rabbit monoclonal antibody has proven to 
be a sensitive but not completely specific marker for IFS.
4
 
B. IFS-like lesions with related kinases fusions. A subset of childhood sarcomas that strongly 
resemble IFS by morphologic criteria (IFS-like sarcomas) harbor recurrent chromosomal 
abnormalities other than ETV6-NTRK3, including EML4-NTRK3 variant fusions and 
rearrangements of the kinase genes ALK, BRAF and NTRK1 (Fig 1), summarized in Table 1.
5-7
 
Most IFS-like sarcomas occur in children under age 2, but some present  at older age with a 
predilection for intra-abdominal sites. Clinical outcome is less predictable with some cases 
showing aggressive clinical behavior, including distant metastases.  
More recently a few cases of IFS have been reported to demonstrate compound intragenic BRAF 
deletions associated with tandem dupplication of exon 2.
8
 Their mechanism of activation is most 
likely similar to the BRAF-related fusions, resulting in loss of the N-terminal of BRAF protein 
containing the negative regulatory Ras-binding domain (RBD), with subsequent constitutive 
activation of BRAF. Interestingly, in that study, 2 of 3 IFS with BRAF intragenic deletions show 
coexisting ETV6-NTRK3 fusions. Further investigations are needed to clarify if these genetic 
abnormalities are subclonal or work synergistically in tumorigenesis, and if they might be related 
to resistance to targeted therapy.  
An additional case with morphologic features of IFS but unusual S100 expression was recently 
reported by our group in a 4-month-old girl with a large, locally agressive pelvic mass.
9
 By 
whole transcriptome sequencing the tumor showed a novel TFG-MET fusion, retaining the MET 
kinase domain. The tumor was composed of cellular fascicles wih monomorphic hyperchromatic 
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tumor showed strong and diffuse S100 expression, whereas SOX10 was negative and 
H3K27me3 retained, an immunoprofile inconsistent with a diagnosis of malignant peripheral 
nerve sheath tumor (MPNST). 
C. Cellular mesoblastic nephroma – shared genetics with IFS.  
Congenital cellular mesoblastic nephroma (CMN), a renal tumor presenting in children during 
the first months of life, often harbours the same recurrent ETV6-NTRK3 fusion found in the 
majority of IFS.
10
 Compared to translocation-negative variants of congenital mesoblastic 
nephroma with classic or mixed histology, the cellular variant with ETV6-NTRK3 fusion carries a 
far better prognosis in terms of relapse free and overall survival.
11
 Some of the genetic alterations 





, and BRAF internal duplications
8
, 
providing further evidence that IFS and CMN are histogenetically related entities. 
 
2. LIPOFIBROMATOSIS-LIKE NEURAL TUMORS AND RELATED ENTITIES 
Lipofibromatosis-like neural tumor (LPF-NT) is a recently defined entity based on its recurrent 
NTRK1 gene fusions. The descriptive designation, LPF-NT, was used to emphasize its close 
resemblance to lipofibromatosis and its incomplete neural immunophenotype with S100 
positivity but negative SOX10.
12,13
 The tumors present in children and young adults as 
superficial, infiltrative lesions in the extremities. A recent case presenting in an infant as a 
pigmented back lesion was recently reported.
14
 Microscopically, LPF-NT are characterized by 
monomorphic spindle cells, haphazardly arranged in a reticular pattern and diffusely infiltrating 
into the subcutaneous fat (Fig. 2). Tumor cells may show a mild degree of nuclear atypia and 
rare mitoses. By IHC, LPF-NT show expression of S100 and varibable positivity for CD34. This 
immunoprofile might suggest an alternative peripheral nerve sheath tumor diagnosis, however, 
tumors consistently lack SOX10 expression. Molecularly, LPF-NT harbor activating NTRK1 
fusions, common gene partners including LMNA, TPR, and TPM3, resulting mostly from intra-
chromosomal interstitial deletions or inversions.
12
 As a result, tumors express NTRK1 (Fig. 2), 
as shown by IHC with either NTRK1 or pan-TRK antibodies.  
The differential diagnosis of LPF-NT also includes lipofibromatosis (LPF) and 
dermatofibrosarcoma protuberans (DFSP). LPF is a childhood tumor, occasionally present at 
birth, which has a predilection for hands and feet. Microscopically, it is composed of  
intersecting long and thin fascicles of fibroblastic spindle cells that infiltrate subcutaneous fat or 
skeletal muscle, a pattern reminiscent of infantile-type fibromatosis. LPF lacks the nodular 
fibromyxoid areas, typically seen in the triphasic morphology of fibrous hamartoma of infancy.
15
 
LPF shows variable expression of CD34 and focal S100 staining, but lacks NTRK1 and beta-
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Pediatric DFSP is rare and typically occurs under a variant morphologic phenotype, described as 
giant cell fibroblastoma. These lesions may mimic both LPF and LPF-NT, due to its honeycomb 
infiltrative growth within subcutis and CD34 reactivity. However, these lesions are consistently 
negative for S100 and harbor in nearly all cases a recurrent COL1A1- PDFGB fusion, resulting 





3. INFLAMMATORY MYOFIBROBLASTIC TUMORS HARBORING FUSIONS 
INVOLVING ALK AND OTHER KINASES 
About half of inflammatory myofibroblastic tumors (IMTs) regardless of anatomic location 
harbor ALK gene rearrangements and overexpress ALK protein. IMTs have a predilection for 
lung, viscera, and soft tissue sites and commonly occur in children and young adults. IMTs 
display a wide morphologic spectrum, ranging from a predominantly inflammatory lesion with a 
paucity of spindle cells and prominent chronic inflammation and/or hyalinized stroma, to a 
highly cellular myofibroblastic proliferation and occasionally frankly sarcomatous neoplasm, 
lacking a significant inflammatory or/and stromal component. Due to its variable morphologic 
phenotype and lack of a consistent immunoprofile, the diagnosis of IMTs in the absence of ALK-
rearrangements, has been often a diagnosis of exclusion with a challenging differential diagnosis 
including at one end of the spectrum reactive/inflammatory processes, such as the fibro-
inflammatory IgG4-related disease, idiopathic retroperitoneal fibrosis, and postoperative 
myofibroblastic proliferations, while at the other end of the spectrum, spindle cell sarcomas with 
myofibroblastic or fibroblastic features. In our recent series of 62 IMTs (25 presenting in 
children), gene rearrangements involving kinases were found in two-thirds of cases, including 
ALK fusions in 56%, ROS1 in 10%, and one case with RET rearrangement.
17
 In that study, 
pediatric IMT showed a 90% rate of kinase fusion-positive results. Furthermore, most IMT with 
EML4-ALK fusions occurred in children, including 2 newborns (range 0-39 years, mean 15). 
Similarly, all except one case of ROS1-rearranged IMTs occurred in the pediatric age group, 
showing slender spindle cells with distinctive long cell processes arranged in loose fascicles, 
with mild inflammatory component and a variably fibromyxoid stroma. ROS1 IHC can be 
applied as a surrogate method for ROS1 rearrangement screening in IMT.
18
 Additionally a 
handful of cases of IMT with ETV6-NTRK3 fusions have also been reported.
19,20
  Importantly, a 





II. NEW GENETIC ADVANCES IN FIBROBLASTIC PEDIATRIC LESIONS 
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Fibrous hamartoma of infancy (FHI) is a rare benign subcutaneous soft tissue tumor, first 
described by Enzinger as a tumor with a distinctive tripartite histological appearance.
23
 FHI is 
more prevalent in boys in the first two years of life. The most common anatomic sites are trunk, 
extremities, head and neck and genital regions. Grossly, FHI is a poorly circumscribed 
subcutaneous fatty mass with a mean size of 3 cm. Microscopically, FHI consists of adipose 
tissue intermixed with long interlacing fascicles of dense fibrous tissue surrounded by 
fibromyxoid nodules consisting of immature spindle cells, an architecture which gives the lesion 
an organoid appearance (Fig. 3).
24,25
 Apart from the typical triphasic histology, up to half of the 
cases have hyalinized areas with dense collagen and long slit-like pseudoangiomatous spaces. By 
IHC, a subset of FHI shows variable expression of smooth muscle actin and CD34, consistent 
with the fibroblastic nature of the tumor. FHI are benign, with a small subset showing local 
recurrence, likely due to incomplete primary excision, in particular of large poorly circumscribed 
tumors. 
The genetic hallmark of FHI, recently coined by NGS and targeted Sanger sequencing, 
represents a somatic EGFR exon 20 insertion/duplication (Fig. 3), likely resulting in oncogenic 
EGFR activation.
26
 Notably, immunohistochemistry applied in that study revealed a moderate 
degree of EGFR protein expression, particularly in the primitive cell component. A similar 
genotype was also reported in FHI with variant histology, including tumors with a predominant 
pseudoangiomatous morphology, which can mimic giant cell fibroblastoma.
27
 No EGFR 
mutations were noted in other fibrolipomatous control cases tested.  
2. FN1-EGF FUSION IN CALCIFYING APONEUROTIC FIBROMA  
Calcifying aponeurotic fibroma (CAF) is a benign fibroblastic tumor with a predilection for the 
soft tissues of the hands and feet, with a peak incidence in the first decade of life.
28,29
 Boys are 
afflicted more often than girls. CAF is a solid, nodular subcutaneous tumor, usually less than 3 
cm in size, often connected to aponeurosis, tendon sheath or joint capsule. Microscopically, the 
tumor is often well-circumscribed, non-encapsulated, although occasionally might have 
infiltrative margins. CAF has a biphasic morphology, composed of bland appearing fibroblasts 
arranged either haphazardly or in short storiform fascicles, which alternate with partly calcified 
fibrocartilage-like nodules. The latter areas show finely granular dystrophic calcifications 
surrounded by hyalinized collagen, with embedded epithelioid fibroblasts resembling 
chondrocytes, as well as scattered osteoclast-type giant cells (Fig. 3). CAF may recur locally, 
particularly in young children. Differential diagnosis includes palmar fibromatosis and soft tissue 
chondroma. The genetics of CAF were recently defined by the presence of a recurrent FN1-EGF 
gene fusion, resulting from a presumed ins(2;4)(q35;q25).
30
 The likely pathogenetic mechanism 
is an inappropriate expression of the biologically active portion of EGF, which can be detected 
immunohistochemically, driven by the strong FN1 promoter activity.  
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An EWSR1-SMAD3 fusion was recently identified as the genetic hallmark of a novel benign 
fibroblastic neoplasm with predilection for acral soft tissues.
31
 The index case occurred in the 
foot of an infant male, presenting as an ill-defined dermal and subcutaneous nodule with an 
infiltrative border. The tumor was composed of intersecting cellular fascicles of uniform plump 
fibroblastic-type spindle cells with bland fusiform nuclei (Fig. 3). Two additional cases 
presenting superficially in the foot of adult women harbored identical gene fusion and histologic 
appearance. However, the adult lesions shared some similarities to CAF, with a distinctive 
zonation pattern, with peripheral hypercellular areas transitioning to hypocellular collagenous 
areas, containing fine granular calcifications. Unsupervised clustering of the whole transcriptome 
data showed that the EWSR1-SMAD3 fusion positive tumor clustered together with other 
fibroblastic tumors, including a CAF with FN1-EGF fusion, a lipofibromatosis lacking genetic 
abnormalities, and a LPF-NT with TPR-NTRK1 fusion. Interestingly, ERG mRNA was strongly 
upregulated, finding further supported by diffuse nuclear immunoexpression of ERG protein.
31
  
III. PERIVASCULAR MYOID TUMORS 
The spectrum of perivascular myoid neoplasms includes myofibroma, myopericytoma, 
angioleiomyoma, and glomus tumor.
32
 It is well recognized that these tumors may have 
overlapping or hybrid histologic features. Their clinical presentation varies with age at diagnosis, 
with myopericytoma, angioleiomyoma, and glomus tumor rarely occurring in children, whereas 
myofibromas may present at any age. Myofibromas are either solitary or multicentric (a.k.a. 
myofibromatosis). Solitary (infantile) myofibroma displays a biphasic histomorphology, 
consisting of fascicles with myofibroblastic cells, alternating with areas of immature spindle 
cells associated with branching hemangiopericytoma-like vessels. Sites of predilection are the 
head and neck region, including tongue and mandible, and upper trunk. Bone and internal organs 
are often involved in myofibromatosis, in addition to soft tissue locations. 
Immunohistochemically, the immature spindle cells in myofibromas may express CD34, whereas 
myofibroblastic cells typically are actin-positive. Myofibromas with myoid or myopericytic 
differentiation may focally express desmin and caldesmon. The molecular genetics of 
perivascular myoid tumors have been only recently elucidated. 
1. PDGFRB MUTATIONS IN MYOFIBROMA(TOSIS) AND MYOPERICYTOMA(TOSIS) 
Recurrent activating mutations in the platelet-derived growth factor receptor beta gene 
(PDGFRB) are found in nearly all autosomal dominant myofibromatosis.
33-35
 In these families 
the PDFGRB R561C hot spot mutation is the most common variant, whereas the P660T and 
P560L variants are relatively rare. Subsequently, various activating PDGFRB mutations were 
detected in cases of nonfamilial myofibromatosis
36
 and in the majority of sporadic myofibromas 
encountered in infants (75%) and adults (69%), with N666K mutation being detected in about 
half of the cases.
37
 These activation mutations are mostly located in the juxtamembrane and 
kinase domains of the PDGFRB receptor and were shown to be sensitive to tyrosine kinase 
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described in a family with myofibromatosis.
34
 NOTCH3 is a regulator of PDGFRB and both 
signaling pathways play an essential role in the proliferation and migration of subsets of 
pericytes and vascular smooth muscle cells during vascular development and angiogenesis. Not 
surprisingly, NOTCH rearrangements and fusions associated with MIR143 have been implicated 
in more than half of glomus tumors; the incidence being much higher in malignant examples.
38
 
In addition to myofibroma(tosis), RNA sequencing also revealed PDGFRB mutations in 
myopericytoma and myopericytomatosis, a condition presenting in the lower extremity of adults, 




2. SRF-RELA FUSION IN CELLULAR MYOFIBROMA/MYOPERICYTOMA 
SRF rearrangements, in particular SRF-RELA fusions, were recently described in a group of 
cellular myofibroblastic tumors with histologic features reminiscent of cellular myofibroma or 
cellular myopericytoma.
40
 Most of these tumors presented in children younger than 18 years of 
age. The few cases with follow-up did not indicate aggressive or metastatic behavior. By IHC, 
these cellular myofibroblastic tumors had a smooth muscle-like phenotype with abundant 
expression of smooth muscle actin, desmin, and caldesmon. Microscopically, two architectural 
patterns were observed, one being composed of monomorphic spindle cells arranged in 
intersecting fascicles, while the other consisted of rounded to ovoid cells arranged in either a 
syncytial growth or a nested architecture around a rich capillary network. Biphasic patterns 
reminiscent of myofibroma were also encountered. SRF-RELA fusions were not encountered in 
classic examples of myofibroma or myopericytoma. 
 
IV. SPINDLE CELL/SCLEROSING RHABDOMYOSARCOMA AND OTHER 
NOVEL MOLECULAR GROUPS 
 
Pediatric rhabdomyosarcomas (RMS) have been traditionally divided into embryonal and 
alveolar subtypes, defined by their different clinical presentation, histologic appearance, and 
outcome. The large majority of alveolar RMS harbor PAX3/7-FOXO1 fusions, while embryonal 
RMS lack a recurrent genetic abnormality. However, in the latest WHO classification, one 
additional independent subgroup was recognized, the so-called ‘spindle and sclerosing RMS’, 
which was separated from the embryonal group based on its distinctive histologic and clinical 
features.
32
 This review focuses mainly on this latter subtype, where most recent molecular 
discoveries have been made. 
 
Spindle cell RMS was originally described as a rare and prognostically favorable variant of 
embryonal RMS in the pediatric age group, mainly presenting in young males as paratesticular 
tumors or in the head and neck region.
41
 A subsequent series of spindle cell RMS in adults 
suggested a more aggressive clinical course compared to pediatric cases.
42
 Histologically, 
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herringbone fascicles intermixed with variable amount of collagen. A subset of these lesions 
shows abundant hyaline collagen deposition with a deceptively bland spindle cell appearance, 
being designated as sclerosing RMS. Of note both spindle and sclerosing subtypes typically lack 
differentiating rhabdomyoblasts or significant nuclear pleomorphism (Fig. 4). Instead, solid areas 
of primitive round cells, reminiscent of a solid alveolar RMS, can be noted, particularly in the 
setting of sclerosing subtype.
43
 In this regard, a recent re-review of the alveolar RMS patients 
enrolled in COG studies from 1999-2005 found that 30% of the tumors were reclassified as 
either embryonal or sclerosing RMS,
44
 the main pitfall being the presence of dense or sclerosing 
patterns. By IHC, spindle and sclerosing RMS shows reactivity for desmin and MyoD1, as well 
as multifocal expression of myogenin. The genetic abnormalities of spindle cell/sclerosing RMS 
were recently characterized, which are distinct from embryonal RMS and vary based on the age 
at presentation and anatomic location. Despite their overlapping morphologic features, at least 
three genomic groups have been defined in the pediatric age group, including: an infantile subset 
of spindle cell RMS harboring VGLL2-related gene fusions, a MYOD1-mutant subset commonly 
associated with sclerosing morphology, and a subset lacking recurrent genetic abnormalities. 
 
1. FUSION-POSITIVE CONGENITAL OR INFANTILE SPINDLE CELL RMS.  
These infantile tumors harbor recurrent gene fusions, involving critical transcriptional activators 
of muscle-specific genes, such as VGLL2, TEAD1 and SRF.
43,45
 The most common variant was 
VGLL2-CITED2 (Fig 4), followed by VGLL2-NCOA2, with rare cases displaying TEAD1-
NCOA2 and SRF-NCOA2. These patients present at birth or within one year of age, with 
predilection for trunk, and follow a favorable clinical outcome, lacking metastatic potential. The 
clinical behavior of fusion-positive infantile spindle cell RMS group resembles that of ETV6-
NTRK3-positive infantile fibrosarcoma; these findings militate against their classification as a 
‘high grade neoplasm’. A recent study however, suggested that VGLL2-fusion positive tumors 
might represent a biologically and pathologically more heterogenous group of tumors than 
initially described.
46
 Based on 7 such cases, 6 positive for VGLL2-NCOA2 and one for VGLL2-
CITED2, the authors describe 2 histologic patterns, including a deceivingly bland ‘fibrous’ 
subtype and a ‘dense’ cellular subtype. Despite their positivity for myogenin and expression of 
muscle-related genes transcriptionally, these tumors did not cluster genomically with other RMS 
samples.  
2. MYOD1-MUTANT SPINDLE CELL/SCLEROSING RMS.   
The presence of transactivating MYOD1 mutations have been described in both spindle cell and 
sclerosing RMS, providing a strong molecular basis in support for their classification as a single 
pathologic entity.
47
 At the molecular level, most tumors harbor a MYOD1 homozygous mutation 
in exon 1 (p.L122R) (Fig. 4), while a smaller subset shows a heterozygous genotype. MYOD1 
regulates muscle cell differentiation by inducing cell cycle arrest, a prerequisite for myogenic 
initiation. Mutation of Leu 122 to Arg in MYOD1 has been shown to confer reduced 
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patients with MYOD1 mutations, with or without accompanying PIK3CA mutations, follow a 
highly aggressive course with high mortality despite multimodality therapy.
47,49,50
 In a recent 
study, MYOD1 mutations were the most common genetic abnormality in pediatric spindle 
cell/sclerosing RMS, occurring in 64% of children beyond one year of age, and suggesting that it 
can be used as a molecular biomarker to stratify these high risk patients.
43
 The head and neck 
location represents the most common site, occurring in one-third of patients, followed by 
extremities and trunk. 
 
3. ‘WILD-TYPE’ SPINDLE CELL/SCLEROSING RMS  
This group encompasses the ‘genetically negative’ group, lacking gene fusions or MYOD1 
mutations, often presenting intra-abdominally or para-testicular. This molecular-negative group 
is typically associated with a favorable clinical course and most likely represents a spindle cell 
variant of embryonal RMS.
51
   
4. NOVEL EPITHELIOID RMS VARIANT DEFINED BY EWSR1/FUS-TFCP2 FUSIONS.  
The presence of EWSR1/FUS-TFCP2 fusions has been recently reported in 3 tumors from young 
adult females occuring with predilection at skeletal sites (pelvis, chest wall, sphenoid bone).
46
 
The tumors were composed of a predominant epithelioid sheet-like growth, although focal areas 
of fascicular spindled cells were also observed. Overall histology including a high mitotic 
activity was in keeping with a high grade malignancy. Their immunoprofile showed positivity 
for desmin, MYOD1, myogenin and ALK. The patients followed a highly aggressive course, 
succombing to disease in less than 6 months. These findings were further confirmed by a recent 
case report of a 72-year-old male with a destructive lesion of the mandible, which harbored a 
similar FUS-TFCP2 fusion.
52
 However, the morphologic findings in this report appear to be 
distinct, the authors describing it as an unusual molecular variant of spindle cell RMS of bone, 
rather than having an epithelioid phenotype. Further studies are needed to establish if this new 
molecular signature defines a novel RMS pathologic entity or simply a genetic variant of spindle 
cell/sclerosing RMS with predilection for skeletal sites.  
 
V. UNDIFFERENTIATED TUMORS WITH BCOR ONCOGENIC ACTIVATION – 
‘BCOR FAMILY OF TUMORS’ 
Undifferentiated sarcomas characterized by BCOR genetic alterations, spanning both gene 
fusions and internal tandem duplications (ITD), share similarities at the morphologic and 
immunohistochemical levels, despite the wide spectrum of clinical presentations and pathologic 
entities involved. BCOR (BCL6 interacting corepressor) is a transcriptional corepressor involved 
in gene suppression by either interacting with BCL6 or binding to PCGF1 (polycomb-group 
RING finger homologue 1) as part of a variant Polycomb Repressive Complex 1 (PRC1.1), 
associated with chromatin remodeling and histone modification.
53
 BCOR genetic abnormalities 
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PUFD domain, responsible of anchoring the C-terminal BCOR to the PCGF1 unit of the PRC1.1 
complex.
54
 Thus formations of gene fusions or ITD most likely alter the binding affinity between 
BCOR and PCGF1, affecting the subsequent recruitment of KDM2B and downstream gene 
regulation.
55
 Regardless of the specific gene alterations, BCOR family of tumors show 
significant upregulation of BCOR and SATB2 mRNA, resulting into protein overexpression and 
immunopositivity for BCOR and SATB2, which can be used as reliable diagnostic markers.
56
.  
1. INFANTILE UNDIFFERENTIATED SOFT TISSUE TUMORS WITH BCOR-INTERNAL 
TANDEM DUPLICATIONS 
In a recent study about half of infantile soft tissue undifferentiated round and spindle cell 
sarcomas harbored recurrent BCOR exon 15 ITD, with rare cases showing instead YWHAE-
NUTM2B fusions.
57
 The cohort included 7 boys and 4 girls, ranging in age from 8 days to 11 
months, involving the soft tissues of the trunk, retroperitoneum/pelvis and head and neck. 
Histologically, the tumors were composed of primitive round to ovoid cells arranged in vague 
nests and compartments delineated by a delicate arborizing vascular network or cellular fibrous 
septa (Fig. 5). A subset of tumors displayed extensive myxoid and cystic changes, highly 
reminiscent of the previously described entity ‘primitive myxoid mesenchymal tumor of infancy 
(PMMTI)’.58 Indeed further molecular analysis of cases previously designated as PMMTI 
showed similar BCOR ITD abnormalities, in keeping with a morphologic spectrum. Moreover, 
as BCOR ITD alterations were described recently as the leading pathogenetic mechanism of clear 
cell sarcoma of kidney (CCSK),
59
 a comparative histologic and genomic analysis of the 2 tumor 
types showed significant overlap with the infantile soft tissue tumors harboring a similar 
genotype.
57
 These findings suggest that BCOR-ITD defines a novel pediatric undifferentiated 
sarcoma, which encompasses tumors previously designated as unclassified infantile primitive 
sarcomas, PMMTI and CCSK (Fig. 5). This unified disease entity shows a homogenous 
immunoprofile, with strong and diffuse positivity for BCOR and SATB2,
57,60
 as a result of 
oncogenic BCOR gene upregulation. Further studies are needed to better define their clinical 
behavior and treatment; particularly if these tumors should be managed with undifferentiated 
sarcoma or CCSK type therapeutic strategies. 
2. BCOR-CCNB3 FUSION POSITIVE PRIMITIVE SARCOMAS  
BCOR-CCNB3 fusion positive sarcoma was first described by Pierron et al.
61
 as a small blue 
round cell malignancy with overlapping demographics and morphology with Ewing sarcoma, but 
showing distinct copy number abnormalities. The genetic hallmark consists of a paracentric 
inversion on the short arm of chromosome X, resulting in the fusion of 2 nearby genes, BCOR 
and CCNB3 (10 Mb apart), leading to CCNB3 overexpression. The initial report suggested a 
strong predilection for male children and skeletal anatomic sites, while two subsequent smaller 
studies showed a more even distribution between bone and soft tissue locations.
62,63
 In a recent 
comprehensive analysis of 36 cases, the clinicopathologic features were further characterized, 










This article is protected by copyright. All rights reserved.
11 
 
predilection for bone anatomic sites.
64
 Kidney was the only visceral location, with one of these 2 
cases presenting in a 12 year-old male with a markedly cystic lesion.
65
  Histologically, the 
tumors displayed a primitive and monomorphic cytology, composed of variable proportions of 
round to spindle cells, arranged in solid sheets or short fascicles, in a sparse myxoid or 
collagenous stroma. In fact, tumors showed significant morphologic overlap with other primitive 
tumors with BCOR genetic abnormalities. Immunohistochemically, tumors showed strong and 
diffuse expression for BCOR and SATB2 (Fig 5).
64
 Follow-up information revealed a similar 
outcome to Ewing sarcoma, with a 5-year overall survival of 72%, but significantly more 
favorable than CIC-DUX4 sarcomas. In keeping with the distinct clinical behavior, the BCOR 
family of tumors (including BCOR-CCNB3, BCOR-ITD) had similar expression signature 
clustering together by unsupervised clustering of RNA sequencing, separate from other primitive 
sarcomas, such as Ewing, CIC-DUX4 and synovial sarcomas.
64
  
3. RELATED TUMORS WITH BCOR UPREGULATION  
Rare cases with alternative BCOR fusions have also been reported, including BCOR-MAML3 and 
ZC3H7B-BCOR, which result from more conventional inter-chromosomal translocations.
66
 
Tumors with these fusions were shown to share significant morphologic and 
immunohistochemical features with other members of the BCOR-family tumors.
56,64
 
Interestingly, about of half of synovial sarcomas also show BCOR overexpression, including rare 
cases with SS18L1-SSX1 fusions.
64,67
 Moreover, in addition to the common BCOR 
overexpression, it was recently recognized the close histologic overlap between tumors with 






[1] Mertens F, Antonescu CR, Mitelman F. Gene fusions in soft tissue tumors: Recurrent and overlapping 
pathogenetic themes. Genes Chromosomes Cancer. 2016;55:291-310. 
[2] Bourgeois JM, Knezevich SR, Mathers JA, et al. Molecular detection of the ETV6-NTRK3 gene fusion 
differentiates congenital fibrosarcoma from other childhood spindle cell tumors. Am J Surg Pathol. 
2000;24:937-946. 
[3] Laetsch TW, DuBois SG, Mascarenhas L, et al. Larotrectinib for paediatric solid tumours harbouring 
NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. Lancet Oncol. 
2018;19:705-714. 
[4] Hung YP, Fletcher CDM, Hornick JL. Evaluation of pan-TRK immunohistochemistry in infantile 
fibrosarcoma, lipofibromatosis-like neural tumour and histological mimics. Histopathology. 2018. 
[5] Church AJ, Calicchio ML, Nardi V, et al. Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and 
congenital mesoblastic nephroma suggest a revised testing strategy. Mod Pathol. 2018;31:463-473. 
[6]  Kao YC, Fletcher CDM, Alaggio R, et al. Recurrent BRAF gene fusions in a subset of pediatric spindle 
cell sarcomas: expanding the genetic spectrum of tumors with overlapping features with infantile 
fibrosarcoma. Am J Surg Pathol. 2018;42:28-38. 
[7] Pavlick D, Schrock AB, Malicki D, et al. Identification of NTRK fusions in pediatric mesenchymal 










This article is protected by copyright. All rights reserved.
12 
 
[8] Wegert J, Vokuhl C, Collord G, et al. Recurrent intragenic rearrangements of EGFR and BRAF in soft 
tissue tumors of infants. Nat Commun. 2018;9:2378. 
[9]  Flucke U, van Noesel MM, Wijnen M, et al. TFG-MET fusion in an infantile spindle cell sarcoma with 
neural features. Genes Chromosomes Cancer. 2017;56:663-667. 
[10]  Rubin BP, Chen CJ, Morgan TW, et al. Congenital mesoblastic nephroma t(12;15) is associated with 
ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma. 
Am J Pathol. 1998;153:1451-1458. 
[11] Vokuhl C, Nourkami-Tutdibi N, Furtwangler R, et al. ETV6-NTRK3 in congenital mesoblastic 
nephroma: A report of the SIOP/GPOH nephroblastoma study. Pediatr Blood Cancer. 2018;65. 
[12] Agaram NP, Zhang L, Sung YS, et al. Recurrent NTRK1 gene fusions define a novel subset of locally 
aggressive lipofibromatosis-like neural tumors. Am J Surg Pathol. 2016;40:1407-1416. 
[13]  Lao IW, Sun M, Zhao M, et al. Lipofibromatosis-like neural tumour: a clinicopathological study of 
ten additional cases of an emerging novel entity. Pathology. 2018;50:519-523. 
[14]  Bartenstein DW, Coe TM, Gordon SC, et al. Lipofibromatosis-like neural tumor: Case report of a 
unique infantile presentation. JAAD Case Rep. 2018;4:185-188. 
[15]  Fetsch JF, Miettinen M, Laskin WB, et al. A clinicopathologic study of 45 pediatric soft tissue tumors 
with an admixture of adipose tissue and fibroblastic elements, and a proposal for classification as 
lipofibromatosis. Am J Surg Pathol. 2000;24:1491-1500. 
[16] Gooskens SL, Oranje AP, van Adrichem LN, et al. Imatinib mesylate for children with 
dermatofibrosarcoma protuberans (DFSP). Pediatr Blood Cancer. 2010;55:369-373. 
[17] Antonescu CR, Suurmeijer AJ, Zhang L, et al. Molecular characterization of inflammatory 
myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement. 
Am J Surg Pathol. 2015;39:957-967. 
[18] Hornick JL, Sholl LM, Dal Cin P, et al. Expression of ROS1 predicts ROS1 gene rearrangement in 
inflammatory myofibroblastic tumors. Mod Pathol. 2015;28:732-739. 
[19] Yamamoto H, Yoshida A, Taguchi K, et al. ALK, ROS1 and NTRK3 gene rearrangements in 
inflammatory myofibroblastic tumours. Histopathology. 2016;69:72-83. 
[20]  Alassiri AH, Ali RH, Shen Y, et al. ETV6-NTRK3 is expressed in a subset of ALK-negative inflammatory 
myofibroblastic tumors. Am J Surg Pathol. 2016;40:1051-1061. 
[21] Theilen TM, Soerensen J, Bochennek K, et al. Crizotinib in ALK(+) inflammatory myofibroblastic 
tumors-Current experience and future perspectives. Pediatr Blood Cancer. 2018;65. 
[22] Lovly CM, Gupta A, Lipson D, et al. Inflammatory myofibroblastic tumors harbor multiple potentially 
actionable kinase fusions. Cancer Discov. 2014;4:889-895. 
[23]  Enzinger FM. Fibrous Hamartoma of Infancy. Cancer. 1965;18:241-248. 
[24]  Saab ST, McClain CM, Coffin CM. Fibrous hamartoma of infancy: a clinicopathologic analysis of 60 
cases. Am J Surg Pathol. 2014;38:394-401. 
[25] Al-Ibraheemi A, Martinez A, Weiss SW, et al. Fibrous hamartoma of infancy: a clinicopathologic 
study of 145 cases, including 2 with sarcomatous features. Mod Pathol. 2017;30:474-485. 
[26]  Park JY, Cohen C, Lopez D, et al. EGFR Exon 20 insertion/duplication mutations characterize fibrous 
hamartoma of infancy. Am J Surg Pathol. 2016;40:1713-1718. 
[27] Ellington N, Park JY, King K, et al. EGFR Exon 20 insertion/duplication mutation in fibrous 
hamartoma of infancy with predominantly pseudoangiomatous pattern mimicking giant cell 
fibroblastoma. Int J Surg Pathol. 2017;25:421-424. 
[28] Allen PW, Enzinger FM. Juvenile aponeurotic fibroma. Cancer. 1970;26:857-867. 
[29] Corominas L, Sanpera I, Jr., Sanpera-Iglesias J, et al. Calcifying aponeurotic fibroma in children: our 
experience and a literature review. J Pediatr Orthop B. 2017;26:560-564. 
[30] Puls F, Hofvander J, Magnusson L, et al. FN1-EGF gene fusions are recurrent in calcifying 










This article is protected by copyright. All rights reserved.
13 
 
[31] Kao YC, Flucke U, Eijkelenboom A, et al. Novel EWSR1-SMAD3 gene fusions in a group of acral 
fibroblastic spindle cell neoplasms. Am J Surg Pathol. 2018;42:522-528. 
[32] Fletcher C, Bridge JA, Hogendoorn PC, et al. WHO Classification of Tumours of Soft Tissue and Bone.   
4th Edition: 115-120: IARC: Lyon; 2013. 
[33] Cheung YH, Gayden T, Campeau PM, et al. A recurrent PDGFRB mutation causes familial infantile 
myofibromatosis. Am J Hum Genet. 2013;92:996-1000. 
[34] Martignetti JA, Tian L, Li D, et al. Mutations in PDGFRB cause autosomal-dominant infantile 
myofibromatosis. Am J Hum Genet. 2013;92:1001-1007. 
[35]  Lepelletier C, Al-Sarraj Y, Bodemer C, et al. Heterozygous PDGFRB mutation in a three-generation 
family with autosomal dominant infantile myofibromatosis. Acta Derm Venereol. 2017;97:858-859. 
[36]  Arts FA, Sciot R, Brichard B, et al. PDGFRB gain-of-function mutations in sporadic infantile 
myofibromatosis. Hum Mol Genet. 2017;26:1801-1810. 
[37]  Agaimy A, Bieg M, Michal M, et al. Recurrent somatic PDGFRB mutations in sporadic 
infantile/solitary adult myofibromas but not in angioleiomyomas and myopericytomas. Am J Surg 
Pathol. 2017;41:195-203. 
[38]  Mosquera JM, Sboner A, Zhang L, et al. Novel MIR143-NOTCH fusions in benign and malignant 
glomus tumors. Genes Chromosomes Cancer. 2013;52:1075-1087. 
[39]  Hung YP, Fletcher CDM. Myopericytomatosis: Clinicopathologic analysis of 11 cases with molecular 
identification of recurrent PDGFRB alterations in myopericytomatosis and myopericytoma. Am J Surg 
Pathol. 2017;41:1034-1044. 
[40]  Antonescu CR, Sung YS, Zhang L, et al. Recurrent SRF-RELA fusions define a novel subset of cellular 
myofibroma/myopericytoma: a potential diagnostic pitfall with sarcomas with myogenic differentiation. 
Am J Surg Pathol. 2017;41:677-684. 
[41] Cavazzana AO, Schmidt D, Ninfo V, et al. Spindle cell rhabdomyosarcoma. A prognostically favorable 
variant of rhabdomyosarcoma. Am J Surg Pathol. 1992;16:229-235. 
[42] Nascimento AF, Fletcher CD. Spindle cell rhabdomyosarcoma in adults. Am J Surg Pathol. 
2005;29:1106-1113. 
[43] Alaggio R, Zhang L, Sung YS, et al. A molecular study of pediatric spindle and sclerosing 
rhabdomyosarcoma: identification of novel and recurrent VGLL2-related fusions in infantile cases. Am J 
Surg Pathol. 2016;40:224-235. 
[44] Rudzinski ER, Anderson JR, Hawkins DS, et al. The World Health Organization classification of 
skeletal muscle tumors in pediatric rhabdomyosarcoma: A report from the Children's Oncology Group. 
Arch Pathol Lab Med. 2015;139:1281-1287. 
[45] Mosquera JM, Sboner A, Zhang L, et al. Recurrent NCOA2 gene rearrangements in 
congenital/infantile spindle cell rhabdomyosarcoma. Genes Chromosomes Cancer. 2013;52:538-550. 
[46]  Watson S, Perrin V, Guillemot D, et al. Transcriptomic definition of molecular subgroups of small 
round cell sarcomas. J Pathol. 2018;245:29-40. 
[47]  Agaram NP, Chen CL, Zhang L, et al. Recurrent MYOD1 mutations in pediatric and adult sclerosing 
and spindle cell rhabdomyosarcomas: evidence for a common pathogenesis. Genes Chromosomes 
Cancer. 2014;53:779-787. 
[48]  Van Antwerp ME, Chen DG, Chang C, et al. A point mutation in the MyoD basic domain imparts c-
Myc-like properties. Proc Natl Acad Sci U S A. 1992;89:9010-9014. 
[49]  Szuhai K, de Jong D, Leung WY, et al. Transactivating mutation of the MYOD1 gene is a frequent 
event in adult spindle cell rhabdomyosarcoma. J Pathol. 2014;232:300-307. 
[50]  Rekhi B, Upadhyay P, Ramteke MP, et al. MYOD1 (L122R) mutations are associated with spindle cell 










This article is protected by copyright. All rights reserved.
14 
 
[51] Leuschner I, Newton WA, Jr., Schmidt D, et al. Spindle cell variants of embryonal 
rhabdomyosarcoma in the paratesticular region. A report of the Intergroup Rhabdomyosarcoma Study. 
Am J Surg Pathol. 1993;17:221-230. 
[52] Dashti NK, Wehrs RN, Thomas BC, et al. Spindle cell rhabdomyosarcoma of bone with FUS-TFCP2 
fusion: confirmation of a very recently described rhabdomyosarcoma subtype. Histopathology. 2018. 
[53]  Gao Z, Zhang J, Bonasio R, et al. PCGF homologs, CBX proteins, and RYBP define functionally distinct 
PRC1 family complexes. Mol Cell. 2012;45:344-356. 
[54]  Junco SE, Wang R, Gaipa JC, et al. Structure of the polycomb group protein PCGF1 in complex with 
BCOR reveals basis for binding selectivity of PCGF homologs. Structure. 2013;21:665-671. 
[55] Wong SJ, Gearhart MD, Taylor AB, et al. KDM2B recruitment of the polycomb group complex, 
PRC1.1, requires cooperation between PCGF1 and BCORL1. Structure. 2016;24:1795-1801. 
[56] Kao YC, Sung YS, Zhang L, et al. BCOR Overexpression is a highly sensitive marker in round cell 
sarcomas with BCOR genetic abnormalities. Am J Surg Pathol. 2016. 
[57] Kao YC, Sung YS, Zhang L, et al. Recurrent BCOR internal tandem duplication and YWHAE-NUTM2B 
fusions in soft tissue undifferentiated round cell sarcoma of infancy: overlapping genetic features with 
clear cell sarcoma of kidney. Am J Surg Pathol. 2016;40:1009-1020. 
[58] Alaggio R, Ninfo V, Rosolen A, et al. Primitive myxoid mesenchymal tumor of infancy: a 
clinicopathologic report of 6 cases. Am J Surg Pathol. 2006;30:388-394. 
[59] Ueno-Yokohata H, Okita H, Nakasato K, et al. Consistent in-frame internal tandem duplications of 
BCOR characterize clear cell sarcoma of the kidney. Nat Genet. 2015;47:861-863. 
[60] Argani P, Pawel B, Szabo S, et al. Diffuse strong BCOR immunoreactivity is a sensitive and specific 
marker for clear cell sarcoma of the kidney (CCSK) in pediatric renal neoplasia. Am J Surg Pathol. 
2018;42:1128-1131. 
[61]  Pierron G, Tirode F, Lucchesi C, et al. A new subtype of bone sarcoma defined by BCOR-CCNB3 gene 
fusion. Nat Genet. 2012;44:461-466. 
[62]  Puls F, Niblett A, Marland G, et al. BCOR-CCNB3 (Ewing-like) sarcoma: a clinicopathologic analysis of 
10 cases, in comparison with conventional Ewing sarcoma. Am J Surg Pathol. 2014;38:1307-1318. 
[63] Peters TL, Kumar V, Polikepahad S, et al. BCOR-CCNB3 fusions are frequent in undifferentiated 
sarcomas of male children. Mod Pathol. 2015;28:575-586. 
[64] Kao YC, Owosho AA, Sung YS, et al. BCOR-CCNB3 fusion positive sarcomas: a clinicopathologic and 
molecular analysis of 36 cases with comparison to morphologic spectrum and clinical behavior of other 
round cell sarcomas. Am J Surg Pathol. 2018;42:604-615. 
[65] Argani P, Kao YC, Zhang L. Primary renal sarcomas with BCOR-CCNB3 Gene Fusion.  A report of 2 
cases showing histologic overlap with clear cell sarcoma of kidney, suggesting further link between 
BCOR-related sarcomas of the kidney and soft tissues. Am J Surg Pathol. 2017 [In Press]. 
[66] Specht K, Zhang L, Sung YS, et al. Novel BCOR-MAML3 and ZC3H7B-BCOR gene fusions in 
undifferentiated small blue round cell sarcomas. Am J Surg Pathol. 2016. 
[67] Kao YC, Sung YS, Zhang L, et al. BCOR upregulation in a poorly differentiated synovial sarcoma with 
















Fig. 1. Pediatric spindle cell sarcomas resembling infantile fibrosarcoma with alternative 
BRAF and NTRK1 gene fusions. Morphologic spectrum showing monomorphic spindle cell 
fascicular growth across various clinicopathologic features and gene fusions, including a 
retroperitoneal lesion in a 16/F showing a SEPT7-BRAF fusion (A, see E diagram); paraspinal 
mass in a 18 months old male with a CUX1-BRAF fusion (B); retroperitoneal tumor in a 7 week 
male showing a TPM3-NTRK1 fusion (C); foot lesion in a 1 year-old male with an EML4-
NTRK3 (D); diagrammatic representation of the SEPT7-BRAF intra-chromosomal translocation, 
resulting in the fusion of SEPT7 exon 11 to BRAF exon 11 (E). 
Fig. 2. Recurrent NTRK1 fusions define lipofibromatosis-like neural tumors. Microscopic 
appearance of a hand soft tissue lesion in a 7 year-old male showing bland short spindle cells 
infiltrating within adipose tissue (A). The tumor cells were diffusely positive for NTRK1 (B). 
The tumor harbored a TPR-NTRK1 fusion by RNA sequencing; diagrammatic representation 
showing the intra-chromosomal break and inversion of the two genes, 29 Mb apart, with opposite 
directions of transcription (C). 
Fig. 3. Benign fibrous lesions of childhood. Microscopic appearance of a fibrous hamartoma 
of infancy (FHI) arising in the left arm in a 11 month-old male showing the typical triphasic 
pattern, composed of adipose tissue intermixed with long interlacing fascicles of dense fibrous 
tissue and fibromyxoid nodules consisting of immature spindle cells (A,B). Microscopic 
appearance of calcifying apeoneurotic fibroma (CAF) arising in the hand of a 7 year-old male 
showing bland fibroblastic type cells embedded in a hyalinized stroma and associated with 
dystrophic calcifications (C). Whole transcriptome RNAsequencing of the FHI case above 
showing an EGFR internal tandem duplication (arrow, CRA unpublished results) (D), which 
resulted in marked upregulation of the EGFR mRNA in this case, compared to other pediatric 
fibroblastic and myofibroblastic lesions (E). CAF case from above harbored a FN1-EGF fusion 
by RNA sequencing, resulting in marked upregulation of EGF mRNA, compared to other soft 
tissue tumors (F). Infantile fibroblastic tumor displaying EWSR1-SMAD3 (G, H), resulting in 
ERG overexpression (I).  
Fig. 4. Spindle cell and sclerosing RMS molecular classification. A. VGLL2-CITED2 fusion 
positive congenital spindle cell RMS diagnosed at birth in the back of a baby-female was 
composed of long intersecting fascicles in a herring-bone pattern of growth; B. MYOD1-mutant 
spindle cell RMS arising in the head and neck of a 9 year-old male showing monomorphic 
spindle cells arranged in vague fascicles; C. Sclerosing RMS from the infratemporal fossa tumor 
arising in a 15 year-old female, showing monomorphic cytomorphology arranged in distinct 
pseudovascular spaces, separated by sclerotic stroma and showing D. diffuse and strong MYOD1 
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in a VGLL2-CITED2 fusion; F. Hot spot L122R exon 1 MYOD1 mutation; arrow indicates a 
heterozygous genotype. 
Fig. 5. BCOR family of tumors show significant morphologic overlap including a primitive 
round to ovoid phenotype arranged in compartments delineated by fibrovascular septae. The 
members of this family include: (A) infantile soft tissue undifferentiated round cell sarcoma with 
BCOR ITD; (B) clear cell sarcoma of the kidney with BCOR ITD; round cell sarcomas with 
either BCOR-MAML3 (C) or BCOR-CCNB3 (D) fusions. The tumors also have in common 
strong and diffuse reactivity for BCOR (E) and SATB2 (F), regardless of the genetic 






















































Table 1. Recently described fusion genes in pediatric sarcomas resembling infantile fibrosarcoma 
Gene abnormality/ fusion Tumor Site  Age Sex Reference # 
 
EML4-NTRK3 foot 21 mo M #6 
EML4- NTRK3 retroperitoneum 7 mo F #5 
EML4- NTRK3 Lung metastasis 1 yr F #5 
EML4- NTRK3 NA 24 days F #8 
SEPT7-BRAF Retroperitoneum 16 yrs F #6 
CUX1-BRAF thoracic spine 18 mo M #6 
BRAF rearranged Pelvis 3 yrs F #6 
BRAF rearranged Pelvis 6 mo F #6 
BRAF rearranged Thigh 2 days M #6 
BRAF intragenic deletion 
 
NA 79 days M #8 














BRAF intragenic deletion co-existing 
ETV6-NTRK3 
NA NA NA #8 
TPM3-NTRK1 Retroperitoneum 7 weeks M #6 
LMNA-NTRK1 Soft tissue, NOS  1 yr M #7 
SQSTM1-NTRK1 Soft tissue, NOS 0 yr F #7 
TFG-MET Pelvic mass 4 mo F #9 
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